These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18546321)

  • 1. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
    Brin MF; Comella CL; Jankovic J; Lai F; Naumann M;
    Mov Disord; 2008 Jul; 23(10):1353-60. PubMed ID: 18546321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
    Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
    Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
    Factor SA; Molho ES; Evans S; Feustel PJ
    Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.
    Rollnik JD; Wohlfarth K; Dengler R; Bigalke H
    Neurol Clin Neurophysiol; 2001; 2001(3):2-4. PubMed ID: 12396862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undesirable distant effects following botulinum toxin type a injection.
    Roche N; Schnitzler A; Genêt F F; Durand MC; Bensmail D
    Clin Neuropharmacol; 2008; 31(5):272-80. PubMed ID: 18836345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term botulinum toxin efficacy, safety, and immunogenicity.
    Mejia NI; Vuong KD; Jankovic J
    Mov Disord; 2005 May; 20(5):592-7. PubMed ID: 15645481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test.
    Cordivari C; Misra VP; Vincent A; Catania S; Bhatia KP; Lees AJ
    Mov Disord; 2006 Oct; 21(10):1737-41. PubMed ID: 16874756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.
    Kessler KR; Benecke R
    Mov Disord; 1997 Jan; 12(1):95-9. PubMed ID: 8990060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
    Comella CL; Jankovic J; Shannon KM; Tsui J; Swenson M; Leurgans S; Fan W;
    Neurology; 2005 Nov; 65(9):1423-9. PubMed ID: 16275831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
    Monheit GD; Cohen JL;
    J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis.
    Trindade de Almeida AR; Marques E; de Almeida J; Cunha T; Boraso R
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S37-43. PubMed ID: 17241413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A for the treatment of nummular headache: four case studies.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Mar; 48(3):442-7. PubMed ID: 18028377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
    Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
    Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A
    Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.